Repatha Shows Safety, Efficacy in Japanese Patients Regardless of Glycemic Status: Subanalysis Data

The PCSK9 inhibitor Repatha (evolocumab) showed sustained efficacy and safety in Japanese hypercholesterolemia patients regardless of baseline glycemic status in PII/III studies, Amgen Astellas BioPharma and Astellas Pharma announced on May 23. The results were from a sub-population analysis of...read more